saRNA influenza vaccine

The saRNA influenza vaccine is an investigational RNA-based vaccine for influenza that utilizes self-amplifying RNA (saRNA) technology. Unlike standard mRNA vaccines, saRNA incorporates genes encoding RNA polymerase complex (replicase) that enable the vaccine RNA to replicate inside host cells, producing more antigen from a smaller starting dose. In preclinical studies, saRNA influenza vaccines encoding hemagglutinin (HA) and neuraminidase (NA) antigens (the main viral surface proteins targeted by immunity) induced robust, cross-reactive immune responses in animal models—even at low doses—offering a potential for effective “dose-sparing”[1][6][9][12]. The saRNA platform’s higher potency per microgram is achieved via both strong antigen expression and enhanced innate immune adjuvancy stemming from double-stranded RNA intermediates generated during replication[1][9]. Clinical trials are ongoing to establish safety and efficacy in humans; current trials employ lipid nanoparticle (LNP) delivery, with most vaccines administered intramuscularly[12]. Developer companies cite potential advantages for both pandemic preparedness and seasonal influenza control, with anticipated benefits in scalability, reduced reactogenicity, and more durable immunity compared to conventional mRNA platforms[6].

Other names

self-amplifying RNA influenza vaccineself-amplifying mRNA influenza vaccinesa-mRNA influenza vaccine